Lead Sponsor

GE Healthcare

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM, melanoma, sarcoma, breast and H\&N cancers.
•The subject has received clinical routine imaging diagnostic work-up within 8 weeks prior to the first \[18F\]AH111585 PET scan.
•The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care.

•The subject has known hyper- or hypo-coagulation syndromes.
•The subject has received chemotherapy within 3 weeks, or received radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to the first \[18F\]AH111585 PET scan.
•The subject is scheduled to undergo chemotherapy, radiotherapy, surgery or any other treatment against cancer between the first and second \[18F\]AH111585 PET scans.
•The subject is scheduled to undergo biopsy for the target tumour between the first and second \[18F\]AH111585 PET scans.
•The subject has intra-hepatic tumour(s) only.
•For the immuno-histochemistry group, the subject's target tumour has been biopsied less than or equal to 1 week prior to the first \[18F\]AH111585 PET scan.

Related studies

NCT06312137 · Non Small Cell Lung Cancer

NCT07042100 · Advanced Solid Tumors

NCT07589530 · Advanced Solid Tumors, Metastatic Solid Tumors, and more

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

NCT07444437 · Non-Small Cell Lung Cancer

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection